The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Being used for drug modification, the multi-arm single molecular weight polyethylene glycol and an active derivative thereof provided herein can effectively improve the solubility, stability, and immunogenicity of the drugs, improve the absorption of the drugs in vivo, prolong the half-life of the drugs, and increase bioavailability, enhance efficacy, and reduce toxic and side effects of the drugs. A gel formed from the active derivative of the multi-arm single molecular weight polyethylene glycol provided herein can be used for the preparation of controlled release drugs so as to prolong the action time of the drugs, thereby reducing the number of administrations and improving patient compliance.

Provided is a polycarbonate polyol used as a raw material of a polyurethane that has an excellent balance of flexibility, mechanical strength and solvent resistance. The polycarbonate polyol includes structural units derived from a polyhydric alcohol and has a hydroxyl value of 20 to 450 mg KOH/g. The polyhydric alcohol includes: a diol (A) containing not less than 70% by weight of a specific oxyalkylene glycol (A1); and a trihydric to hexahydric branched alcohol (B) having 3 to 12 carbon atoms. In the polycarbonate polyol, structural units derived from the branched alcohol (B) is contained in an amount of 0.005 to 5.0% by mole in the structural units derived from the polyhydric alcohol. A ratio of a structural unit (X1) represented by the following Formula (X1) in the structural units derived from the branched alcohol (B) is not higher than 50% by mole. ##STR00001##

A curable glass coating composition including 5-70 wt % aliphatic polycarbonate diol, 5-60 wt % crosslinker, 1-20 wt % extender, 4-20 wt % fatty alcohol, and 2-30 wt % crystalline or amorphous powder filler material, and optionally 2-20 wt % aliphatic polyester polyol and 2-20 wt % cycloaliphatic epoxy. The coating composition can be applied to a glass substrate and cured to form a decorative cured polyurethane coating layer on the substrate that has improved caustic and UV resistance.

A curable glass coating composition including 5-70 wt % aliphatic polycarbonate diol, 5-60 wt % crosslinker, 1-20 wt % extender, 4-20 wt % fatty alcohol, and 2-30 wt % crystalline or amorphous powder filler material, and optionally 2-20 wt % aliphatic polyester polyol and 2-20 wt % cycloaliphatic epoxy. The coating composition can be applied to a glass substrate and cured to form a decorative cured polyurethane coating layer on the substrate that has improved caustic and UV resistance.

Methods of forming a C.sub.4 to C.sub.7 diol compound, the methods including a first step of reacting a C.sub.4 to C.sub.7 dicarboxylic acid with hydrogen (H.sub.2) gas on a first heterogeneous catalyst at a first temperature and a first pressure to form a C.sub.4 to C.sub.7 lactone; and a subsequent step of reacting the lactone with hydrogen (H.sub.2) gas on a second heterogeneous catalyst at a second temperature and a second pressure, wherein the second temperature is lower than the first temperature. Also disclosed are methods of forming a solvent, the methods including reacting a C.sub.4 to C.sub.7 dicarboxylic acid with hydrogen (H.sub.2) gas on a first heterogeneous catalyst at a first temperature and a first pressure to form a solvent. Further disclosed herein are methods that include reacting mevalonolactone with hydrogen (H.sub.2) gas on a second heterogeneous catalyst at a second temperature and a second pressure to form a diol compound.

Methods of forming a C.sub.4 to C.sub.7 diol compound, the methods including a first step of reacting a C.sub.4 to C.sub.7 dicarboxylic acid with hydrogen (H.sub.2) gas on a first heterogeneous catalyst at a first temperature and a first pressure to form a C.sub.4 to C.sub.7 lactone; and a subsequent step of reacting the lactone with hydrogen (H.sub.2) gas on a second heterogeneous catalyst at a second temperature and a second pressure, wherein the second temperature is lower than the first temperature. Also disclosed are methods of forming a solvent, the methods including reacting a C.sub.4 to C.sub.7 dicarboxylic acid with hydrogen (H.sub.2) gas on a first heterogeneous catalyst at a first temperature and a first pressure to form a solvent. Further disclosed herein are methods that include reacting mevalonolactone with hydrogen (H.sub.2) gas on a second heterogeneous catalyst at a second temperature and a second pressure to form a diol compound.

A method of isolating and purifying a product of sugar alcohol or anhydrosugar alcohol hydrogenolysis from a reaction mixture containing sorbitans, 1,2,4-butanetriol (BTO), 1,2,5,6-hexanetetrol (HTO), among other byproducts of a hydrogenolysis reaction of a sugar alcohol and/or a mono- or di-dehydrative product of a sugar alcohol is described. The method involves contacting the mixture having the products of sugar alcohol or anhydrosugar alcohol hydrogenation and other C.sub.1-C.sub.6 alcohols and polyols with a resin material adapted for chromatography under conditions where the products preferentially associates with the resin relative to other components in the mixture, and eluting products from the resin with a solvent. The method suggests a way for separation of aliphatic polyols generated from the hydrogenolysis of sugar alcohols or anhydrosugar alcohols.

A method of isolating and purifying a product of sugar alcohol or anhydrosugar alcohol hydrogenolysis from a reaction mixture containing sorbitans, 1,2,4-butanetriol (BTO), 1,2,5,6-hexanetetrol (HTO), among other byproducts of a hydrogenolysis reaction of a sugar alcohol and/or a mono- or di-dehydrative product of a sugar alcohol is described. The method involves contacting the mixture having the products of sugar alcohol or anhydrosugar alcohol hydrogenation and other C.sub.1-C.sub.6 alcohols and polyols with a resin material adapted for chromatography under conditions where the products preferentially associates with the resin relative to other components in the mixture, and eluting products from the resin with a solvent. The method suggests a way for separation of aliphatic polyols generated from the hydrogenolysis of sugar alcohols or anhydrosugar alcohols.

The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.